



Media release

Japanese Patent Office issues Notice of Allowance for Transmucosal Delivery Patent

Melbourne Australia 22 January 2019: Invictus BioPharma Ltd, the Company commercialising an innovative new non-invasive and direct drug and vitamin delivery platform, says the Japanese Patent Office has issued a Notice of Allowance for the Company's patent for the transmucosal delivery of tocotrienols.

The patent covers the use of the vitamin and drug delivery technology for the treatment or prevention of post exercise muscle soreness and delayed onset muscle soreness. A divisional application has been filed to pursue different aspects of the drug and vitamin delivery technology.

The patent formally entitled 'Transmucosal Delivery of Tocotrienol' will provide commercial rights in Japan until 13 November 2032.

Invictus BioPharma Executive Chairman and CEO Dr Glenn Tong said "The granting of the Japanese patent comes at an opportune time when our nutraceutical products are about to be launched in the US and we are exploring partnerships to enter the Japanese and European markets."

"Japan is a significant market for nutraceuticals and pharmaceuticals and the granting of this latest patent provides additional validation of Invictus BioPharma's patent estate" he said.

Invictus BioPharma has corresponding patents granted in Australia, New Zealand, Singapore and South Africa. A notice of intention to grant in the EU has been issued and patent applications are pending in other major markets including the US.

For more information please contact:

Dr Glenn Tong
Invictus BioPharma Ltd.
Tel: 0412 193 350

Andrew Geddes
CityPR
Tel: 02 9267 4511

About Invictus BioPharma Ltd.

Invictus BioPharma Ltd. is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. Invictus BioPharma owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: www.invictusbiopharma.com